Alira Health

Alira Health

CMS Issues Proposed Rule to Cover ‘Breakthrough’ Medical Devices

News
Published on:
August 11, 2020

The Centers for Medicare & Medicaid Services (CMS) issued a proposed rule this week that would give breakthrough medical devices national Medicare coverage on the same day they receive FDA approval for four years. The proposed rule, called Medicare Coverage of Innovative Technology (MCIT), would establish a Medicare coverage pathway that provides beneficiaries nationwide with faster access to new, innovative medical devices designated as ‘breakthrough’ by the Food and Drug Administration (FDA).

During the four year timeframe, CMS recommends that manufacturers develop additional evidence showing the applicability of their products to Medicare beneficiaries so they can apply for further coverage.

Before the MCIT, after a breakthrough technology receives FDA approval, an often lengthy and costly process for Medicare coverage begins. That period has been challenging for companies because innovators spent time and resources to achieve FDA approval, only to need to spend more time and money to acquire Medicare coverage. This lag time is not only costly but has also reduced access to innovative technologies by senior populations.

This proposed rule follows up on creating a pathway to Medicare coverage the same day as FDA market authorization for breakthrough devices. The proposal will be live from September 1, 2020 and open for comment till October 30, 2020. Additionally, the proposed rule would allow Medicare to cover eligible breakthrough devices the FDA has approved for use in 2019 or 2020.

What does it mean for you?

Organizations will need to understand the details of the breakthrough designation and how it applies to their innovation before proceeding. Moreover, what evidence needs to be generated in these four years to maintain coverage. The Alira Health team can help you understand how this designation applies to you, and how you can best leverage the proposed rule for your innovation.

For more information, please contact Deepak Sahu.

Click here to see the proposed rule from The Department of Health and Human Services.

Related news

Reports May 20, 2024
Innovative Payment Schemes for Medtech in England, Germany, and France
This overview offers high-level details on the innovative payment schemes in England, Germany, and France.
MedTech
Case Studies May 14, 2024
Medtech Company Creates an Early Go-to-Market Strategy for Its Breakthrough IVD Solution
The client needed an early go-to-market strategy for their IVD solution to prepare for product development and launch in key European countries and the US.
IVDR Medical Devices MedTech
Case Studies May 8, 2024
Mid-Size Medtech Company with a Borderline Product Defines Strategy for EU Launch
Medtech company sought support in developing a regulatory strategy for the EU launch of their product with an aggressive timeline to launch.
Medical Devices MedTech Regulatory
Reports May 8, 2024
Value-Based Procurement in Australia
This white paper discusses why value-based healthcare and procurement are solutions in a robust healthcare system and identifies the medical technology sector as a collaborative partner(...)
MedTech Value-Based Contracts
Case Studies April 30, 2024
Medtech Company Leverages Bayesian Clinical Trial Design to Address FDA Feedback
A global medtech company needed help to address FDA feedback on their implant design that included a comparator and clearly demonstrated the safety and performance of this new device.
Clinical Trials Complex Innovative Design MedTech
Events April 30, 2024
The MedTech Forum 2024
We are thrilled to announce that we will exhibit and speak at The MedTech Forum 2024.
MedTech Regulatory
News April 29, 2024
Alira Health Advises Trill Impact Entering a Strategic Alliance with TT medic
We are pleased to have been a Commercial Due Diligence advisor for Trill Impact, a pioneering Impact House with around EUR 1.2 billion in assets under management, joining forces with(...)
CDD CDMO MedTech
Welcome to Alira Health. This site is best viewed in Chrome, Microsoft Edge, or Firefox.